Search results
David Abramowitz is Co-Chair of Locke Lord's FDA Regulatory Group and focuses his practice on complex patent litigation brought under the Hatch-Waxman amendments to the Federal Food, Drug and Cosmetic Act and the Biologics Price, Competition, and Innovation Act, where he has significant experience representing and counseling generic ...
Co-Chair FDA Regulatory Practice at Locke Lord LLP - Hatch-Waxman Litigator and Food, Drug, and Cosmetic Regulatory Specialist.
- 292
- 296
- Locke Lord LLP
- Chicago, Illinois, United States
Mar 19, 2024 · David Abramowitz, a Chicago Partner in Locke Lord’s IP Pharmaceutical Practice Group and Co-Chair of the Firm’s FDA Regulatory Group, was quoted by The Guardian about California’s proposed Assembly Bill 2316, which would ban certain food additives in school meals if passed.
David Abramowitz and Carolyn Blessing will speak at the 8th Annual Paragraph IV Disputes Master Symposium in Chicago on September 21-22, 2022.
Dec 14, 2023 · A new era of cosmetics is around the bend and Locke Lord’s FDA Regulatory and Cosmetic and Personal Care teams can help you prepare for what is to come.
Dec 21, 2023 · For a review of the MoCRA’s requirements with respect to reporting serious adverse events please see Locke Lord QuickStudy: Prepare for MoCRA’s New Adverse Event Requirements Now.
David Abramowitz. Co-Chair FDA Regulatory Practice at Locke Lord LLP - Hatch-Waxman Litigator and Food, Drug, and Cosmetic Regulatory Specialist. 4mo. An important update for everyone in...
